Management of Anti-allogeneic Antibody Elimination by Apheresis in Living Donor Liver Transplantation
: In this study, we report on the indications and efficacy of the elimination of antiallogeneic antibodies in living donor liver transplant recipients. Seven patients incompatible with the ABO‐blood type were subjected to apheresis before transplantation. The procedure resulted in titers being decr...
Gespeichert in:
| Veröffentlicht in: | Therapeutic apheresis and dialysis 2007-10, Vol.11 (5), p.319-324 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 324 |
|---|---|
| container_issue | 5 |
| container_start_page | 319 |
| container_title | Therapeutic apheresis and dialysis |
| container_volume | 11 |
| creator | Kawagishi, Naoki Takeda, Ikuo Miyagi, Shigehito Satoh, Kazushige Akamatsu, Yorihiro Sekiguchi, Satoshi Fujimori, Keisei Sato, Toshinobu Satomi, Susumu |
| description | : In this study, we report on the indications and efficacy of the elimination of antiallogeneic antibodies in living donor liver transplant recipients. Seven patients incompatible with the ABO‐blood type were subjected to apheresis before transplantation. The procedure resulted in titers being decreased to less than a score of 8. After transplantation, apheresis was also performed in 6 cases and continuous hemodiafiltration in 1 case. In addition, three out of 11 ABO‐blood type incompatible recipients were administered anti‐CD20 antibody (rituximab). Two crossmatch positive patients were subjected to apheresis before transplantation, and in these cases the titers were reduced to less than a score of 2. Moreover, these two patients had no acute rejections after transplantation. We concluded that apheresis is effective for preventing acute rejection induced by pre‐existing anti‐A and/or anti‐B antibodies, as well as antidonor specific antibodies, but is not effective in some patients who had accelerated humoral rejection. |
| doi_str_mv | 10.1111/j.1744-9987.2007.00506.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68263822</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68263822</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5446-4535f0e9fbd8480a6636ec537daeb47d050c68d077551ee00131b32c68485d1b3</originalsourceid><addsrcrecordid>eNqNkEuP0zAUhS0EYoaBv4C8YpfgxM9IbKoyD6TOwKLMsLOc5Ka4JHbHTqH99zhtVbZ443Pt811fH4RwQfIirY_rvJCMZVWlZF4SInNCOBH57gW6PF-8PGtZXaA3Ma4JKUtG6Wt0UUjFOK3IJYJ748wKBnAj9h2eudFmpu_9ChzY5lDXvt3j694O1pnReofrPZ5tfkKAaCO2Di_sb-tW-LN3PkwFBLwMxsVNb9x4QN6iV53pI7w77Vfo-831cn6XLb7efpnPFlnDGRNZmol3BKqubhVTxAhBBTScytZAzWSbPtkI1RIpOS8ACCloUdMynTHF2ySv0Idj303wz1uIox5sbKBPg4DfRi1UKagqy2RUR2MTfIwBOr0JdjBhrwuip4j1Wk_p6SlJPUWsDxHrXULfn97Y1gO0_8BTpsnw6Wj4Y3vY_3djvZx9SyLh2RG3cYTdGTfhlxaSSq6fHm71482Pu8enaq45_QtY8pnO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68263822</pqid></control><display><type>article</type><title>Management of Anti-allogeneic Antibody Elimination by Apheresis in Living Donor Liver Transplantation</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Kawagishi, Naoki ; Takeda, Ikuo ; Miyagi, Shigehito ; Satoh, Kazushige ; Akamatsu, Yorihiro ; Sekiguchi, Satoshi ; Fujimori, Keisei ; Sato, Toshinobu ; Satomi, Susumu</creator><creatorcontrib>Kawagishi, Naoki ; Takeda, Ikuo ; Miyagi, Shigehito ; Satoh, Kazushige ; Akamatsu, Yorihiro ; Sekiguchi, Satoshi ; Fujimori, Keisei ; Sato, Toshinobu ; Satomi, Susumu</creatorcontrib><description>: In this study, we report on the indications and efficacy of the elimination of antiallogeneic antibodies in living donor liver transplant recipients. Seven patients incompatible with the ABO‐blood type were subjected to apheresis before transplantation. The procedure resulted in titers being decreased to less than a score of 8. After transplantation, apheresis was also performed in 6 cases and continuous hemodiafiltration in 1 case. In addition, three out of 11 ABO‐blood type incompatible recipients were administered anti‐CD20 antibody (rituximab). Two crossmatch positive patients were subjected to apheresis before transplantation, and in these cases the titers were reduced to less than a score of 2. Moreover, these two patients had no acute rejections after transplantation. We concluded that apheresis is effective for preventing acute rejection induced by pre‐existing anti‐A and/or anti‐B antibodies, as well as antidonor specific antibodies, but is not effective in some patients who had accelerated humoral rejection.</description><identifier>ISSN: 1744-9979</identifier><identifier>EISSN: 1744-9987</identifier><identifier>DOI: 10.1111/j.1744-9987.2007.00506.x</identifier><identifier>PMID: 17845390</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>ABO Blood-Group System - immunology ; ABO incompatible ; Adolescent ; Adult ; Apheresis ; Blood Group Incompatibility - therapy ; Blood Grouping and Crossmatching ; Child ; Child, Preschool ; Crossmatch positive ; Female ; Humans ; Infant ; Isoantibodies - isolation & purification ; Liver Transplantation ; Living donor liver transplantation ; Living Donors ; Male ; Middle Aged ; Plasmapheresis - methods ; Rituximab</subject><ispartof>Therapeutic apheresis and dialysis, 2007-10, Vol.11 (5), p.319-324</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5446-4535f0e9fbd8480a6636ec537daeb47d050c68d077551ee00131b32c68485d1b3</citedby><cites>FETCH-LOGICAL-c5446-4535f0e9fbd8480a6636ec537daeb47d050c68d077551ee00131b32c68485d1b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1744-9987.2007.00506.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1744-9987.2007.00506.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17845390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kawagishi, Naoki</creatorcontrib><creatorcontrib>Takeda, Ikuo</creatorcontrib><creatorcontrib>Miyagi, Shigehito</creatorcontrib><creatorcontrib>Satoh, Kazushige</creatorcontrib><creatorcontrib>Akamatsu, Yorihiro</creatorcontrib><creatorcontrib>Sekiguchi, Satoshi</creatorcontrib><creatorcontrib>Fujimori, Keisei</creatorcontrib><creatorcontrib>Sato, Toshinobu</creatorcontrib><creatorcontrib>Satomi, Susumu</creatorcontrib><title>Management of Anti-allogeneic Antibody Elimination by Apheresis in Living Donor Liver Transplantation</title><title>Therapeutic apheresis and dialysis</title><addtitle>Ther Apher Dial</addtitle><description>: In this study, we report on the indications and efficacy of the elimination of antiallogeneic antibodies in living donor liver transplant recipients. Seven patients incompatible with the ABO‐blood type were subjected to apheresis before transplantation. The procedure resulted in titers being decreased to less than a score of 8. After transplantation, apheresis was also performed in 6 cases and continuous hemodiafiltration in 1 case. In addition, three out of 11 ABO‐blood type incompatible recipients were administered anti‐CD20 antibody (rituximab). Two crossmatch positive patients were subjected to apheresis before transplantation, and in these cases the titers were reduced to less than a score of 2. Moreover, these two patients had no acute rejections after transplantation. We concluded that apheresis is effective for preventing acute rejection induced by pre‐existing anti‐A and/or anti‐B antibodies, as well as antidonor specific antibodies, but is not effective in some patients who had accelerated humoral rejection.</description><subject>ABO Blood-Group System - immunology</subject><subject>ABO incompatible</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Apheresis</subject><subject>Blood Group Incompatibility - therapy</subject><subject>Blood Grouping and Crossmatching</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Crossmatch positive</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Isoantibodies - isolation & purification</subject><subject>Liver Transplantation</subject><subject>Living donor liver transplantation</subject><subject>Living Donors</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Plasmapheresis - methods</subject><subject>Rituximab</subject><issn>1744-9979</issn><issn>1744-9987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkEuP0zAUhS0EYoaBv4C8YpfgxM9IbKoyD6TOwKLMsLOc5Ka4JHbHTqH99zhtVbZ443Pt811fH4RwQfIirY_rvJCMZVWlZF4SInNCOBH57gW6PF-8PGtZXaA3Ma4JKUtG6Wt0UUjFOK3IJYJ748wKBnAj9h2eudFmpu_9ChzY5lDXvt3j694O1pnReofrPZ5tfkKAaCO2Di_sb-tW-LN3PkwFBLwMxsVNb9x4QN6iV53pI7w77Vfo-831cn6XLb7efpnPFlnDGRNZmol3BKqubhVTxAhBBTScytZAzWSbPtkI1RIpOS8ACCloUdMynTHF2ySv0Idj303wz1uIox5sbKBPg4DfRi1UKagqy2RUR2MTfIwBOr0JdjBhrwuip4j1Wk_p6SlJPUWsDxHrXULfn97Y1gO0_8BTpsnw6Wj4Y3vY_3djvZx9SyLh2RG3cYTdGTfhlxaSSq6fHm71482Pu8enaq45_QtY8pnO</recordid><startdate>200710</startdate><enddate>200710</enddate><creator>Kawagishi, Naoki</creator><creator>Takeda, Ikuo</creator><creator>Miyagi, Shigehito</creator><creator>Satoh, Kazushige</creator><creator>Akamatsu, Yorihiro</creator><creator>Sekiguchi, Satoshi</creator><creator>Fujimori, Keisei</creator><creator>Sato, Toshinobu</creator><creator>Satomi, Susumu</creator><general>Blackwell Publishing Asia</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200710</creationdate><title>Management of Anti-allogeneic Antibody Elimination by Apheresis in Living Donor Liver Transplantation</title><author>Kawagishi, Naoki ; Takeda, Ikuo ; Miyagi, Shigehito ; Satoh, Kazushige ; Akamatsu, Yorihiro ; Sekiguchi, Satoshi ; Fujimori, Keisei ; Sato, Toshinobu ; Satomi, Susumu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5446-4535f0e9fbd8480a6636ec537daeb47d050c68d077551ee00131b32c68485d1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>ABO Blood-Group System - immunology</topic><topic>ABO incompatible</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Apheresis</topic><topic>Blood Group Incompatibility - therapy</topic><topic>Blood Grouping and Crossmatching</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Crossmatch positive</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Isoantibodies - isolation & purification</topic><topic>Liver Transplantation</topic><topic>Living donor liver transplantation</topic><topic>Living Donors</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Plasmapheresis - methods</topic><topic>Rituximab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawagishi, Naoki</creatorcontrib><creatorcontrib>Takeda, Ikuo</creatorcontrib><creatorcontrib>Miyagi, Shigehito</creatorcontrib><creatorcontrib>Satoh, Kazushige</creatorcontrib><creatorcontrib>Akamatsu, Yorihiro</creatorcontrib><creatorcontrib>Sekiguchi, Satoshi</creatorcontrib><creatorcontrib>Fujimori, Keisei</creatorcontrib><creatorcontrib>Sato, Toshinobu</creatorcontrib><creatorcontrib>Satomi, Susumu</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic apheresis and dialysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawagishi, Naoki</au><au>Takeda, Ikuo</au><au>Miyagi, Shigehito</au><au>Satoh, Kazushige</au><au>Akamatsu, Yorihiro</au><au>Sekiguchi, Satoshi</au><au>Fujimori, Keisei</au><au>Sato, Toshinobu</au><au>Satomi, Susumu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Anti-allogeneic Antibody Elimination by Apheresis in Living Donor Liver Transplantation</atitle><jtitle>Therapeutic apheresis and dialysis</jtitle><addtitle>Ther Apher Dial</addtitle><date>2007-10</date><risdate>2007</risdate><volume>11</volume><issue>5</issue><spage>319</spage><epage>324</epage><pages>319-324</pages><issn>1744-9979</issn><eissn>1744-9987</eissn><abstract>: In this study, we report on the indications and efficacy of the elimination of antiallogeneic antibodies in living donor liver transplant recipients. Seven patients incompatible with the ABO‐blood type were subjected to apheresis before transplantation. The procedure resulted in titers being decreased to less than a score of 8. After transplantation, apheresis was also performed in 6 cases and continuous hemodiafiltration in 1 case. In addition, three out of 11 ABO‐blood type incompatible recipients were administered anti‐CD20 antibody (rituximab). Two crossmatch positive patients were subjected to apheresis before transplantation, and in these cases the titers were reduced to less than a score of 2. Moreover, these two patients had no acute rejections after transplantation. We concluded that apheresis is effective for preventing acute rejection induced by pre‐existing anti‐A and/or anti‐B antibodies, as well as antidonor specific antibodies, but is not effective in some patients who had accelerated humoral rejection.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>17845390</pmid><doi>10.1111/j.1744-9987.2007.00506.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1744-9979 |
| ispartof | Therapeutic apheresis and dialysis, 2007-10, Vol.11 (5), p.319-324 |
| issn | 1744-9979 1744-9987 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68263822 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | ABO Blood-Group System - immunology ABO incompatible Adolescent Adult Apheresis Blood Group Incompatibility - therapy Blood Grouping and Crossmatching Child Child, Preschool Crossmatch positive Female Humans Infant Isoantibodies - isolation & purification Liver Transplantation Living donor liver transplantation Living Donors Male Middle Aged Plasmapheresis - methods Rituximab |
| title | Management of Anti-allogeneic Antibody Elimination by Apheresis in Living Donor Liver Transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T01%3A38%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Anti-allogeneic%20Antibody%20Elimination%20by%20Apheresis%20in%20Living%20Donor%20Liver%20Transplantation&rft.jtitle=Therapeutic%20apheresis%20and%20dialysis&rft.au=Kawagishi,%20Naoki&rft.date=2007-10&rft.volume=11&rft.issue=5&rft.spage=319&rft.epage=324&rft.pages=319-324&rft.issn=1744-9979&rft.eissn=1744-9987&rft_id=info:doi/10.1111/j.1744-9987.2007.00506.x&rft_dat=%3Cproquest_cross%3E68263822%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68263822&rft_id=info:pmid/17845390&rfr_iscdi=true |